Close Menu

NEW YORK (GenomeWeb) – OmniSeq said today that Hitachi High-Technologies has taken an option to exclusively license its OmniSeq Comprehensive and Immune Report Card tests for clinical distribution in Japan after participating in the company's Series B funding round.

OmniSeq — a subsidiary of the Roswell Park Comprehensive Cancer Center — said it plans to use the funds from the Series B to conduct ongoing retrospective and prospective clinical trials and to generate evidence of the clinical utility of its comprehensive genomic and immune profiling services. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.